Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 7/20 | 0.54 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | CTSC | P53634 | 1/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937742 | 0.84 | CTSC (0.49) | LRRK2CTSCJAK3 | |
| SCHEMBL1937791 | 0.83 | CTSC (0.53) | NTRK1LRRK2CTSCJAK3 | |
| SCHEMBL1937794 | 0.82 | CTSC (0.51) | NTRK1CTSCSTK17BSTK17AJAK3 | |
| SCHEMBL2516943 | 0.82 | CDK1 (0.51) | NTRK1LRRK2CTSCSTK17BSTK17A | |
| SCHEMBL1936618 | 0.82 | NTRK1 (0.47) | NTRK1LRRK2CTSCSTK17BSTK17A | |
| SCHEMBL1936527 | 0.79 | JAK2 (0.44) | LRRK2CTSCJAK3 | |
| SCHEMBL1937672 | 0.78 | JAK2 (0.48) | LRRK2CTSCJAK3 | |
| SCHEMBL1937806 | 0.74 | JAK3 (0.42) | NTRK1LRRK2CTSCJAK3 | |
| SCHEMBL1937120 | 0.74 | JAK3 (0.47) | LRRK2CTSCJAK3 | |
| SCHEMBL13622515 | 0.73 | CTSC (0.58) | LRRK2CTSCJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245249-A1 | Heterocyclically Substituted Anilinopyrimidines | BAYER CROPSCIENCE AG (DE) | 2011-10-06 | — | — | US | disclosed |
| EP-2331533-A1 | HETEROCYCLICALLY SUBSTITUTED ANILINOPYRIMIDINES AS FUNGICIDES | Bayer CropScience AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010025850-A1 | HETEROCYCLICALLY SUBSTITUTED ANILINOPYRIMIDINES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245249-A1 | Heterocyclically Substituted Anilinopyrimidines | POLL, H1-2, H1-0 | PRKCQ 2677/4885SOS1 2059/4885NTRK1 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.